4D Molecular announces CF Foundation will provide $11M for 4D-710

4D Molecular (FDMT) Therapeutics announced that the Cystic Fibrosis Foundation will provide up to $11M in additional funding, with an initial tranche of $7.5 million, and technical support to accelerate the development of 4D-710 for the treatment of cystic fibrosis lung disease. This support includes the creation of a new Joint Steering Committee, JSC, with senior clinical development and regulatory expertise to enhance strategic planning, guidance, and coordination of 4D-710’s development. With this funding, the CF Foundation has committed nearly $32 million to 4DMT CF programs to date.